Abstract
Chinese hamster ovary (CHO) cells produced the majority of complex recombinant therapeutic proteins in the biopharmaceutical industry. Improvements in the production of therapeutic proteins in CHO cells will lead to substantial advancement in the biotechnology industry and ultimately increase the availability of the high impact pharmaceutical products. Despite the numerous efforts that have been made to increase productivity and quality of therapeutic proteins produced in CHO cells, many challenges remain. The underlying biology of productivity in CHO cells has not yet been elucidated due to the insufficiency of systematic and in-depth studies. Meanwhile, evaluating quality of therapeutic proteins still faces many difficulties due to the complex structure and function of recombinant therapeutic proteins. Mass spectrometry-based quantitative proteomics that can globally characterize CHO cells and CHO cell-produced therapeutic proteins in great depth can play a significant role in addressing these challenges.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
